Nearly 40,000 eye drops recalled after FDA issues Class II warning risk.

This claim remains unverified. Multiple secondary reports describe a nationwide recall involving almost 40,000 Clear Eyes bottles because of a potential sterility or contamination issue, yet the supplied material lacks a primary FDA document confirming the precise count, Class II classification, or a warning specifically directed at Clear Eyes.

FDA warns consumers not to purchase or use certain eye drops from several major brands due to risk of eye infection
Source: fda.gov

FDA warns consumers not to purchase or use certain eye drops from several major brands due to risk of eye infection
Source: fda.gov

At a glance

Key Evidence

Verified August 20, 2026

The Economic Times, Mint, USA on August 20, 2026, and WSLS describe a 2026 nationwide recall affecting nearly 40,000 eye-drop bottles.
The Economic Times and Mint identify the product as Clear Eyes Maximum Itchy Eye Relief.
AOL gives the count as 39,060 and describes the action as Class II, but no supporting FDA classification document is included.
The FDA materials provided concern other products or earlier incidents and do not establish a Clear Eyes-specific warning.

The reporting

What the Evidence Shows

The available material lends partial support to the reported recall. Several articles dated August 19 and 20, 2026, state that nearly 40,000 bottles of Clear Eyes Maximum Itchy Eye Relief were recalled across the country because of a possible contamination concern. One report specifies a total of 39,060 bottles.

Several significant details, however, are not established by the supplied sources:

The product identity, bottle count, lot details, and national distribution are documented only in secondary coverage. The packet contains no original 2026 FDA notice, enforcement entry, or statement from the manufacturer.
AOL labels the incident an FDA Class II recall, but no FDA document in the packet verifies that designation. A Fox Business article discusses a separate Class II recall involving Lupin steroid eye drops, so it cannot substantiate the classification for Clear Eyes.
The reports refer to possible contamination or uncertainty about sterility. They do not show that contamination was definitively confirmed.
The FDA page supplied relates to different eye-drop products and an incident from 2023. It neither names Clear Eyes Maximum Itchy Eye Relief nor shows that FDA issued a warning specifically about that product. The claim may be blending a recall category with an FDA warning or risk communication.

Since the statement combines a partially corroborated recall report with unverified claims about FDA involvement and classification, the supplied evidence does not justify a True or Mostly True rating.

Primary trail